Bicuspid aortic valve (BAV) is a congenital defect in which the aortic valve has two rather than three leaflets. In many patients valve function may be normal but valve decompensation may occur due to other associated congenital abnormalities and secondary valve and aortic complications. Decompensation manifests as stenosis or regurgitation and thoracic aortic aneurysm and dissection. Cystic medial necrosis plays an important role in the pathogenesis of BAV. Prevalence of BAV is estimated at 0.5-2.0%. In children, 70-85% of stenotic aortic valves are bicuspid, compared to at least 50% in adults. BAV has autosomal dominant inheritance. This Utility Gene Test was developed on the basis of an analysis of the literature and existing diagnostic protocols. It is useful for confirming diagnosis, as well as for differential diagnosis, couple risk assessment and access to clinical trials.
electrocardiogram, chest radiogram, integration of septal and color Doppler with two-dimensional echocardiography, angiography by retrograde femoral arterial catheterization and angio-NMR (nuclear magnetic resonance), spin-echo MR imaging, CT, diagnostic catheterization and genetic testing.
Differential diagnosis should consider aortic coarctation, interruption of the aortic arch and hypoplastic left heart syndrome.
BAV has autosomal dominant inheritance with incomplete penetrance and variable expressivity (3) .
Non-syndromic BAV (3, 11, 12, 13)
• Aortic valve disease 1 (AOVD1, OMIM disease 109730) -NOTCH1 (OMIM gene 190198); • Aortic valve disease 2 (AOVD2, OMIM disease 614823) -SMAD6 (OMIM gene 602931); • GATA5 (OMIM gene 611496); • AXIN1 (OMIM gene 603816); • NKX2-5 (OMIM gene 600584).
Syndromic BAV (13-15)
• Marfan syndrome (MFS, OMIM disease 154700) -FBN1
(OMIM gene 134797); • Loeys-Dietz syndrome 1,2 and 4 (LDS1, LDS2 and LDS4, OMIM diseases: 609192, 610168 and 614816) -TGFBR1 (OMIM gene 190181), TGFBR2 (OMIM gene 190182), TGFB2 (OMIM gene 190220); • Andersen-Tawil syndrome (ATS, OMIM disease 170390) -KCNJ2 (OMIM gene 600681); • Aortic aneurysm, familial thoracic 6 (AAT6, OMIM disease 611788) -ACTA2 (OMIM gene 102620).
Other likely candidate genes for BAV (12, 14, 16) AXIN2 Other research associates ZEB2 (OMIM gene 605802) with a complex syndrome manifesting with intellectual disability, facial dysmorphia, speech delay, hydronephrosis, bicuspid aortic valve and absence of corpus callosum (18) and MATR3 (OMIM gene 164015) with bicuspid aortic valve, aortic coarctation and patent ductus arteriosus (19) .
Pathogenic variants may include missense, nonsense, splicing, small indels, small insertions and deletions, gross insertions and deletions, and complex rearrangements.
Aims of the test
• To determine the gene defect responsible for the disease;
• To confirm clinical diagnosis;
• To assess the recurrence risk and perform genetic counselling for at-risk/affected individuals.
Test characteristics Specialist centers/ Published Guidelines
The test is listed in the Orphanet database and is offered by 12 accredited medical genetic laboratories in the EU, and in the GTR database, offered by 1 accredited medical genetic laboratories in the US. Guidelines for clinical use of the test are described in "Genetics Home Reference" (ghr.nlm.nih.gov).
Test strategy
Clinically distinguishable syndromes can be analyzed by sequencing only those genes known to be associated with that specific disease using Sanger or Next Generation Sequencing (NGS); if the results are negative, or more generally if clinical signs are ambiguous for diagnosis, a multi-gene NGS panel is used to detect nucleotide variations in coding exons and flanking introns of the above genes.
Potentially causative variants and region with low coverage are Sanger-sequenced. Sanger sequencing is also used for family segregation studies.
Multiplex Ligation Probe Amplification (MLPA) is used to detect duplications and deletions in FBN1, NKX2-5, TGFBR1 and KCNJ2.
To perform molecular diagnosis, a single sample of biological material is normally sufficient. This may be 1 ml peripheral blood in a sterile tube with 0.5 ml K 3 EDTA or 1 ml saliva in a sterile tube with 0.5 ml ethanol 95%. Sampling rarely has to be repeated.
Gene-disease associations and the interpretation of genetic variants are rapidly developing fields. It is therefore possible that the genes mentioned in this note may change as new scientific data is acquired. It is also possible that genetic variants today defined as of "unknown or uncertain significance" may acquire clinical importance.
Genetic test results

Positive
Identification of pathogenic variants in the above genes confirms the clinical diagnosis and is an indication for family studies.
A pathogenic variant is known to be causative for a given genetic disorder based on previous reports or predicted to be causative based on the loss of protein function or expected significant damage to protein or protein/protein interactions. In this way it is possible to obtain a molecular diagnosis in new/ other subjects, establish the risk of recurrence in family members and plan preventive and/or therapeutic measures.
Inconclusive
Detection of a variant of unknown or uncertain significance (VUS): a new variation without any evident pathogenic significance or a known variation with insufficient evidence (or with conflicting evidence) to indicate it is likely benign or likely pathogenic for a given genetic disorder. In these cases, it is advisable to extend testing to the patient's relatives to assess variant segregation and clarify its contribution. In some cases, it could be necessary to perform further examinations/tests or to do a clinical reassessment of pathological signs.
Negative
The absence of variations in the genomic regions investigated does not exclude a clinical diagnosis but suggests the possibility of:
• alterations that cannot be identified by sequencing, such as large rearrangements that cause loss (deletion) or gain (duplication) of extended gene fragments; • sequence variations in gene regions not investigated by this test, such as regulatory regions (5' and 3' UTR) and deep intronic regions; • variations in other genes not investigated by the present test.
Unexpected
Unexpected results may emerge from the test, for example information regarding consanguinity, absence of family correlation or other genetically based diseases.
Risk for progeny
In autosomal dominant transmission, the probability that an affected carrier transmit the variant to his/her children is 50% in any pregnancy, irrespective of the sex of the child conceived.
Incomplete penetrance and/or variable expressivity may influence the manifestation of clinical symptoms in individuals harboring a disease-causing variation.
Limits of the test
The test is limited by current scientific knowledge regarding the gene and disease. 
Analytical sensitivity (proportion of positive tests
Clinical sensitivity (proportion of positive tests if the disease is present) and clinical specificity (proportion of negative tests if the disease is not present)
Clinical sensitivity: the variations in the aforementioned genes are associated with BAV, but in many cases, these are individual variations (identified in one or few families) and total epidemiological data is therefore not available. Clinical sensitivity will be estimated based on internal cases (20) .
Clinical specificity: data not available.
Prescription appropriateness
The genetic test is appropriate when: a) the patient meets the diagnostic criteria for BAV; b) the sensitivity of the test is greater than or equal to that of tests described in the literature.
Clinical utility
Clinical management Utility
Confirmation of clinical diagnosis Yes
Differential diagnosis Yes
Couple risk assessment Yes
Availability of clinical trials can be checked on-line at https://clinicaltrials.gov/
